首页> 中国专利> 预防和治疗虚血—再灌流障碍的药物

预防和治疗虚血—再灌流障碍的药物

页面导航

摘要
著录项
法律信息
相似文献

摘要

本发明提供一种预防及治疗虚血—再灌流障碍的药。该药的特征是含有类凝血酶作为有效成分，用于对心肌虚血时，脑虚血时等的再灌流障碍的预防和治疗。

著录项

公开/公告号CN1145809A

专利类型发明专利
公开/公告日1997-03-26

原文格式PDF
申请/专利权人东菱药品工业株式会社;
展开▼

申请/专利号CN96108240.2
发明设计人东丸贵信;匡培根;
展开▼

申请日1996-06-28
分类号A61K38/43;
代理机构中国专利代理(香港)有限公司;
代理人杨丽琴
地址日本东京都
入库时间 2023-12-17 12:52:21

法律信息

法律状态公告日

法律状态信息

法律状态
2016-07-27

专利权有效期届满 IPC(主分类):A61K38/43 授权公告日:20050202 申请日:19960628

专利权的终止
2005-02-02

授权

授权
1998-09-23

实质审查请求的生效

实质审查请求的生效
1997-03-26

公开

公开

相似文献

专利
中文文献
外文文献

1. 预防和治疗虚血—再灌流障碍的药物 [P] . 中国专利： CN1145809A . 1997-03-26
2. 局部缺血再灌流障碍预防和治疗剂 [P] . 中国专利： CN1290169A . 2001-04-04
3. compound of formula i; pharmaceutical composition; method of treating disorders that are related to or affected by inhibition of norepinephrine reuptake, the 5-ht6 receptor or the 5-ht2a receptor; a method of treating a learning disorder, a cognitive disorder, a memory disorder, a personality disorder, a behavioral disorder, a movement disorder, a neurodegenerative disorder, drug withdrawal disorder, sleep, an eating disorder, acute drug toxicity, a cardiovascular disorder, a sexual dysfunction, a gastrointestinal disorder, a genitourinary disorder, a pain disorder, a nervous disorder or a symptom disorder vasomotor; method of treating alzheimer's disease, attention deficit disorder, schizophrenia, parkinson's disease, tardive dyskinesia, ataxia, bradykinesia, paroxysmal dyskinesias, restless leg syndrome, tremor, essential tremor epilepsy, stroke or head trauma; method of treating coronary artery disease, myocardial infarction, transient ischemic attack, angina, atrial fibrillation, p [P] . BRPI0706523A2 . 2011-01-04

机译：式I化合物;药物组合物;治疗与去甲肾上腺素再摄取，5-ht6受体或5-ht2a受体相关或受其抑制的疾病的方法;一种治疗学习障碍，认知障碍，记忆障碍，人格障碍，行为障碍，运动障碍，神经退行性疾病，戒断药物，睡眠，进食障碍，急性药物毒性，心血管疾病的方法，性功能障碍，胃肠道疾病，泌尿生殖系统疾病，疼痛疾病，神经疾病或症状-血管舒缩;治疗阿尔茨海默氏病，注意力缺陷障碍，精神分裂症，帕金森氏病，迟发性运动障碍，共济失调，运动迟缓，阵发性运动障碍，不安腿综合征，震颤，原发性震颤癫痫，中风或头部外伤的方法;治疗冠状动脉疾病，心肌梗塞，短暂性脑缺血发作，心绞痛，心房颤动，p的方法
4. In view of their capability to antagonize the actions of neurokinins by blocking the neurokinin receptors, and in particular antagonizing the actions of substance P by blocking the NK1 receptor, the compounds according to the invention are useful as a medicine, in particular in the prophylactic and therapeutic treatment of neurokinin-mediated conditions, such as, for instance CNS disorders, in particular depression, anxiety disorders, stress-related disorders, sleep disorders, cognitive disorders, personality disorders, schizoaffective disorders, eating disorders, neurodegenerative diseases, addiction disorders, mood disorders, sexual dysfunction, pain and other CNS-related conditions; inflammation; allergic disorders; emesis; gastrointestinal disorders, in particular irritable bowel syndrome (IBS); skin disorders; vasospastic diseases; fibrosing and collagen diseases; disorders related to immune enhancement or suppression and rheumatic diseases and body weight control. [P] . EA009217B1 . 2007-12-28

机译：考虑到它们通过阻断神经激肽受体来拮抗神经激肽的作用，特别是通过阻断NK1受体来拮抗P物质的作用的能力，根据本发明的化合物可用作药物，特别是在预防和治疗中。治疗神经激肽介导的疾病，例如中枢神经系统疾病，尤其是抑郁症，焦虑症，与压力有关的疾病，睡眠障碍，认知障碍，人格障碍，精神分裂性障碍，进食障碍，神经退行性疾病，成瘾障碍，情绪疾病，性功能障碍，疼痛和其他中枢神经系统相关疾病;炎;过敏性疾病呕吐胃肠道疾病，特别是肠易激综合症（IBS）;皮肤疾病;血管痉挛性疾病;纤维化和胶原蛋白疾病;与免疫增强或抑制，风湿性疾病和体重控制有关的疾病。
5. Pharmaceutical composition containing saredutant with a selective serotonin reuptake inhibitor or an inhibitor of the reuptake of serotonin / norepinephrine; and use in Prevention andThe Treatment of major depressive disorder. [P] . CL2007002217A1 . 2008-03-07

机译：药物组合物，其含有含有选择性5-羟色胺再摄取抑制剂或5-羟色胺/去甲肾上腺素再摄取抑制剂的芥子酸;并用于预防和治疗重度抑郁症。